Education
About Us
Working with TipRanks
Follow Us
Amicus Therapeutics (FOLD)
NASDAQ:FOLD
FOLD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.85 - $12.65
Previous CloseN/A
Volume320.41K
Average Volume (3M)2.75M
Market Cap
$2.44B
Enterprise Value$3.01B
Total Cash (Recent Filing)$33.56M
Total Debt (Recent Filing)$3.49M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
May 07, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding307,239,840
10 Day Avg. Volume3,164,471
30 Day Avg. Volume2,752,786
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.12
Price to Cash Flow (P/CF)-172.50
P/FCF Ratio96.90
Enterprise Value/Market Cap1.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.33
Enterprise Value/Ebitda102.44
Forecast
1Y Price Target
$16.22Price Target Upside103.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
---
Amicus News
PremiumCompany Announcements
Amicus Therapeutics Navigates Potential Risks Amid U.S. Trade Policy Changes
PremiumCompany Announcements
Amicus Therapeutics Shines with Strong Earnings Call
---
Bulls Say, Bears Say
Bulls Say
Market Share GrowthGalafold holds over 65% of the global amendable market share with an opportunity to move higher as mature markets are reaching 85-90% of market share.
Regulatory ApprovalsThe therapy was recently approved in Australia, two additional regulatory approvals are expected in 2025 (Japan and Canada), and up to 10 launch countries are expected this year.
Revenue GrowthThe expected revenue growth is anticipated to drive the franchise to profitability.
Bears Say
Clinical ChallengesThe lack of clinical catalysts is a challenge for leveraging the global footprint effectively.
Industry RisksFOLD faces risks common to the biotech industry, including development, regulatory, and manufacturing challenges.
Patient Addition ChallengesThe number of patients on treatment implies a plateauing of patient additions, which is not surprising given no new launch countries in recent quarters combined with the holiday season.
---
Ownership Overview
1.12% Insiders
28.49% Mutual Funds
37.15% Other Institutional Investors
17.09% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FOLD FAQ
What was Amicus Therapeutics’s price range in the past 12 months?
Amicus Therapeutics lowest stock price was $7.84 and its highest was $12.65 in the past 12 months.
What is Amicus Therapeutics’s market cap?
Amicus Therapeutics’s market cap is $2.44B.
When is Amicus Therapeutics’s upcoming earnings report date?
Amicus Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 33 days.
How were Amicus Therapeutics’s earnings last quarter?
Amicus Therapeutics released its earnings results on Feb 19, 2025. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.012 by $0.038.
Is Amicus Therapeutics overvalued?
According to Wall Street analysts Amicus Therapeutics’s price is currently Undervalued.
Does Amicus Therapeutics pay dividends?
Amicus Therapeutics does not currently pay dividends.
What is Amicus Therapeutics’s EPS estimate?
Amicus Therapeutics’s EPS estimate is -0.05.
How many shares outstanding does Amicus Therapeutics have?
Amicus Therapeutics has 307,239,840 shares outstanding.
What happened to Amicus Therapeutics’s price movement after its last earnings report?
Amicus Therapeutics reported an EPS of $0.05 in its last earnings report, beating expectations of $0.012. Following the earnings report the stock price went down -2.944%.
Which hedge fund is a major shareholder of Amicus Therapeutics?
Currently, no hedge funds are holding shares in FOLD
---
Amicus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.22 (103.00% Upside)
$16.22 (103.00% Upside)
Blogger Sentiment
Bullish
FOLD Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 4.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.72%
12-Months-Change
Fundamentals
Return on Equity
-31.68%
Trailing 12-Months
Asset Growth
0.92%
Trailing 12-Months
Company Description
Amicus Therapeutics
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
---
FOLD Company Deck
---
FOLD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Amicus Therapeutics reported strong financial and operational performance with significant revenue growth driven by successful product launches and strategic market expansion. Despite currency exchange rate exposures and regulatory complexities, the company's outlook remains positive with targets for continued revenue growth and improved profitability.Read More>---
FOLD Stock 12 Month Forecast
Average Price Target
$16.22
▲(103.00% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Bluebird Bio
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering FOLD
1 Year
1 Year Success Rate
7/14 ratings generated profit
1 Year Average Return
+21.41%
reiterated a buy rating last month
Copying Debjit Chattopadhyay's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +21.41% per trade.
---